KSPHF:OTCMKTS
Kissei Pharmaceutical Co Ltd
US$ २४.५०
०.००%
(०.००) 1D
अक्टोबर १, १०:२१:४३ GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KSPHF...
Mkt. cap
१.७५ खरब
Avg. vol.
२०.००
Volume
०.००
52-wk high
US$ ३१.९०
52-wk low
US$ २४.५०
Beta
१३.९४
Shares outstanding
४.६५ करोड
No. of employees
२ हजार
Mkt. cap
१.७५ खरब
Avg. vol.
२०.००
Volume
०.००
52-wk high
US$ ३१.९०
52-wk low
US$ २४.५०
Beta
१३.९४
Shares outstanding
४.६५ करोड
No. of employees
२ हजार
News stories
From web sources and news partners
www.marketscreener.com
·
४६ मिनेट पहिले
Nextdoor Holdings, Inc. Primary Exchange Listing will Change to Nasdaq Capital Market from New York Stock Exchange
TipRanks
·
२४ मिनेट पहिले
Hyundai Motor Securities Prices S&P 500-Linked Bond, Raises KRW 8.24 Billion
CNBC
·
३ घण्टा पहिले
Jim Cramer says the bull market's remarkable 4-year run offers a crucial lesson for investors
Yahoo Finance
·
७ घण्टा पहिले
Not Sandisk, Not Intel. This Stock Will Lead the S&P 500 Next Year
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees१.७९ हजार
Founded१९४६ अगस्ट ९
HeadquartersMatsumoto, Nagano, जापान
Sector-
Websitekissei.co.jp